Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01881243 · ClinicalTrials.gov registry record

Reoxygenation After Cardiac Arrest (REOX Study)

A clinical trial of Cardiac Arrest, sponsored by The Cooper Health System.

Completed
Registry status
280
Enrollment target
5
Study locations

NCT01881243: Completed study of Cardiac Arrest, sponsored by The Cooper Health System.

NCT01881243 is a study of Cardiac Arrest that has completed, run by The Cooper Health System. The registered enrollment target is 280 participants, below the 1,471-participant average among 31 other Cardiac Arrest trials with a reported enrollment target (81% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01881243, a study of Cardiac Arrest, has completed, sponsored by The Cooper Health System.

COMPLETED
Registry status
280 participants
Enrollment target
5
Study locations

Study Summary

The broad objective of this study is to test the association between hyperoxia exposure after resuscitation from cardiac arrest and outcome. Our overarching hypothesis is that hyperoxia after ROSC is associated with increased oxidative stress and worsened neurological and cognitive outcomes.

Conditions Studied

Study Locations (5)

Indiana

  • Indiana University/ Methodist Hospital - Indianapolis

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

Mississippi

  • University of Mississippi Medical Center - Jackson

New Jersey

  • Cooper University Hospital - Camden

Pennsylvania

  • Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 280 participants
Start Date 2013-06
Est. Completion 2017-06
The Cooper Health System

39 total trials

What the finished NCT01881243 record still lists

NCT01881243 is an observational study that tracks outcomes without assigning an intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, below the 1,471-participant average among 31 other Cardiac Arrest trials with a reported enrollment target (81% lower).

The record links to 1 condition, with Cardiac Arrest appearing as the primary indexed condition, and to 0 interventions.

NCT01881243 lists 5 locations in 5 states (Indiana, Massachusetts, Mississippi).

Frequently Asked Questions

What is clinical trial NCT01881243 about?

NCT01881243 is a clinical study titled "Reoxygenation After Cardiac Arrest (REOX Study)". The broad objective of this study is to test the association between hyperoxia exposure after resuscitation from cardiac arrest and outcome. Our overarching hypothesis is that hyperoxia after ROSC is associated with increased oxidative stress and worsened neurological and cognitive outcomes.

What is the current status of trial NCT01881243?

This trial is currently completed. The enrollment target is 280 participants. The study started on 2013-06. Estimated completion is 2017-06.

What conditions does trial NCT01881243 study?

This clinical trial studies the following conditions: Cardiac Arrest.

Who is sponsoring clinical trial NCT01881243?

This trial is sponsored by The Cooper Health System, which has 39 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01881243 being conducted?

This trial has 5 study locations across Indiana, Massachusetts, Mississippi, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiac Arrest

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01881243's enrollment target sits among peer trials

280 13th of 31 higher than 19 of 31 other Cardiac Arrest trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cardiac Arrest trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04084730 · 280 participants · Phase 2

    Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer

  • NCT04518657 · 280 participants · NA

    Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis

  • NCT04634916 · 280 participants · NA

    Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System

  • NCT04829617 · 280 participants · NA

    Promoting Well-being and Health in Heart Failure

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01881243, the US trial registry maintained by the National Library of Medicine. NCT01881243 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.